Agenus Stock Surges After Securing $85 Million in Private Placement

Agenus Inc. (NASDAQ:AGEN) announced it has secured $85 million in a private placement financing, sending its shares soaring in premarket trading Monday. The deal, led by Commodore Capital, could potentially raise up to $340 million if associated warrants are fully exercised.

The Financing Deal

Agenus entered into a securities purchase agreement that provides $85 million in upfront gross proceeds. The financing also includes purchase warrants which, upon full exercise, could provide an additional $255 million in funding to the company.

According to the announcement, the transaction was led by Commodore Capital, with participation from a syndicate of investors including RA Capital Management, TCGX, Invus, and Ligand Pharmaceuticals.

Strategic Implications

Ad

The company stated that the proceeds will be used to fund its ROBBIN Phase 3 trial. This capital infusion is projected to extend Agenus's cash runway through the end of 2031, a significant operational extension that is contingent on the full exercise of the purchase warrants.

In a related strategic move, Agenus also announced it will discontinue financial support for its BATTMAN Phase 3 study in late-line metastatic MSS colorectal cancer. This decision allows the company to reallocate resources and focus on its primary clinical programs.

Market Reaction

Investors responded positively to the news, with shares of Agenus climbing 13% in Monday's premarket trading session. The financing is viewed by the market as a significant de-risking event, securing the company's medium-term funding needs and signaling strong confidence from established healthcare investors.